Hemophilia in transition: What plan sponsors need to know now

Hemophilia care is at an inflection point. After decades of relative stability built around factor replacement therapy, the market has entered a period of accelerated innovation—introducing non-factor prophylaxis, extended half-life products, and FDA-approved gene therapies (FDA Hemgenix, FDA Roctavian). For plan sponsors and payers, this evolution presents both opportunity and complexity.

The challenge today is no longer whether innovation works, but how to integrate new therapies responsibly—balancing improved outcomes with predictability, affordability, and long-term population management.

Hemophilia management: From stable standards to a multi-modal treatment landscape

Historically, hemophilia management followed a predictable pattern: routine prophylaxis with factor VIII or IX, punctuated by episodic treatment for breakthrough bleeds. Advances such as recombinant manufacturing and extended half-life factors improved safety and reduced infusion burden, while keeping utilization relatively transparent.

That predictability has shifted. Non‑factor therapies have redefined prophylaxis for both hemophilia A and hemophilia B patients by reducing treatment frequency and stabilizing bleed control through subcutaneous administration, as reflected in recent FDA approvals of Alhemo (concizumab‑mtci) and Hympavzi (marstacimab‑hncq). At the same time, gene therapy has moved from pipeline discussion to clinical reality, fundamentally changing how payers must think about lifetime cost, risk distribution, and outcomes measurement.

For plans, the result is a heterogeneous population in which members may move between factor, non-factor, and gene-based modalities over time—each with distinct clinical, operational, and financial implications.

Gene therapy for hemophilia: Transformative, but not one-size-fits-all

Gene therapy represents the most profound shift in hemophilia care to date. A single administration may enable endogenous clotting factor production for years, significantly reducing bleeding events and ongoing prophylactic spend (Hemgenix FDA approval, Roctavian FDA approval). However, gene therapy is not curative in the traditional sense, nor is it appropriate for every member.

Eligibility criteria, liver health considerations, durability uncertainty, and the inability to re-dose using the same viral vector mean that some patients will eventually require a return to traditional or non-factor therapies. For plan sponsors, this underscores the importance of viewing gene therapy not as a replacement for existing care models, but as one component within a broader treatment continuum.

The financial implications are equally complex. While gene therapy may offset long-term costs for select members, the upfront expense introduces volatility that challenges traditional annual budgeting and forecasting approaches.

The predictability imperative for payers

As therapeutic choice expands, predictability has become the defining requirement for sustainable hemophilia management. Plan sponsors must be able to:

• Forecast utilization across multiple therapy classes
• Understand when high-cost events are likely to occur
• Minimize waste and dosing inefficiencies
• Measure real-world outcomes beyond clinical trial endpoints

Without these capabilities, innovation risks creating variability that undermines both affordability and access.

Specialty pharmacy as a strategic partner

In this environment, specialty pharmacy plays a critical role that extends far beyond distribution. Effective programs function as an extension of the payer—integrating clinical expertise, utilization management, and data-driven insights to support informed decision-making.

Key areas of value include:

• Therapy optimization: aligning product selection and dosing strategies with evidence-based guidelines and member needs
• Waste reduction: mitigating unnecessary spend through vial management and dose optimization
• Gene therapy readiness: supporting site-of-care coordination, eligibility evaluation, and long-term monitoring
• Data transparency: translating complex utilization and outcomes data into actionable insights for payers

Looking ahead: A portfolio approach to hemophilia care

The future of hemophilia management will not be defined by a single therapy or breakthrough. Instead, it will require a portfolio-based approach—one that recognizes the value of choice while maintaining guardrails around cost, quality, and member experience.

For plan sponsors, success will depend on partnering with organizations that can integrate innovation into a predictable, outcomes-focused framework. With the right specialty pharmacy infrastructure in place, hemophilia care can continue to advance in ways that are both clinically meaningful and economically sustainable.

Originally published on 5/24/2023 and updated on 3/24/2026.